Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03207555
Title Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.